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SUMMARY Solar lentigines are benign, brownish lesions that occur 
on light exposed skin surfaces from age 30 onwards, as a sign of 
photoaging. As they are of cosmetic importance to many patients, different 
therapeutic modalities have been tried to remove these unwanted spots. 
The recent development of short-pulsed, pigment-specific lasers has 
enabled physicians to selectively destroy the pigment within the solar 
lentigo lesions with significant clinical improvement, low risk of adverse 
effects, and high patient acceptance. Therefore this therapeutic option is 
superior to traditional treatment modalities and represents the treatment 
of choice in the management of solar lentigines. A case is reported of 
the successful use of Q-switched ruby laser in the treatment of solar 
lentigo on the face. 
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INTRODUCTION
 Solar lentigines are the most common hyper-
melanotic lesions of photoaged skin. They occur 
from age 30 onwards as benign hyperpigmented 
lesions on chronically sun-exposed areas of the 
face, back of the hands, and extensor surfaces of 
the forearms. The lesions vary in size from 0.2 to 
2.0 cm; the intensity of their pigmentation is not 
related to the amount of solar radiation and they 
do not bleach in seasons with little sunlight. The 
spots increase in number with advancing age. 
Although lentigines are not premalignant lesions, 
they are significant cosmetic nuisance for many 
middle-aged and elderly patients (1).
 A number of synonyms have been used for so-
lar lentigines reflecting the relation with age and 
chronic sun exposure: sun-induced freckles, sun-
burn freckles, freckles in adulthood, age spots, 
senile and actinic lentigines. Several studies have 
confirmed these spots to be more prevalent with 
increasing age, and found them to be associated 
with chronic cumulative sun exposure and cutane-
ous signs of aging. They are also related to the 
accumulation of intermittent sun exposure and 
painful sunburns before age 20 (2,3). 
 The most prominent histological features of so-
lar lentigo include hyperpigmentation of the basal 
cell layer with a marked increase in the number 
of melanocytes and small acanthotic protrusions. 
Solar lentigo may be difficult to distinguish from 
other pigmented lesions present on the skin of al-
most all elderly patients, including flat seborrheic 
keratoses, flat pigmented actinic keratoses, ephe-
lides and nevocellular nevi. Probably many solar 
lentigines are initially verruca plana-like sebor-
rheic keratoses (1,4,5). 
 Solar lentigines have been treated with a num-
ber of modalities, including chemical and instru-
mental approaches. Topical tretinoin, depigment-
ing agents, and to a lesser extent alpha-hydroxy 
acids have been used with variable results. Surgi-
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cal procedures such as liquid nitrogen cryotherapy, 
chemical peeling with trichloroacetic acid, phenol 
and alpha-hydroxy acids and dermabrasion are 
also widely used. Most recently, laser surgery has 
imposed as the treatment of choice for solar len-
tigines because of its ability to selectively destroy 
pigment without injury to surrounding tissue. The 
last but not the least, photoprotection from early 
childhood may prevent the appearance of these 
lesions (limitation of mid-day sun exposure, UVA 
and UVB sunscreens, photoprotective clothing, 
etc.) (3-8).
LASER PRINCIPLES
 Recent technologic advancements in cutane-
ous laser surgery have provided a safe and reli-
able means for treating many cutaneous concerns 
and congenital defects, including pigmentaed le-
sions. The original idea of using lasers to remove 
pigment-containing lesions belongs to Leon Gold-
man, who pioneered the use of ruby laser (694 
nm) in the early 1960s to treat different skin le-
sions, including pigmentary disorders (9). Cuta-
neous laser surgery was revolutionized in 1983, 
when Anderson and Parish proposed the theory of 
selective photothermolysis. The theory describes 
how controlled destruction of targeted lesion is 
possible with minimal damage to the adjacent tis-
sues. To achieve this selective effect, 3 require-
ments must be achieved: first, the emitted wave-
length must be absorbed preferentially by the in-
tended tissue target or chromophore (molecules 
with unique absorption spectra which are respon-
sible for imparting color to substances); second, 
the energies produced by laser systems should 
be sufficiently high to inflict thermal damage to the 
target; and third, the time of tissue exposure to the 
laser must be shorter than the thermal relaxation 
time (defined as the time required for the targeted 
side to cool to one half of its peak temperature im-
mediately after laser irradiation) to limit the dam-
age to the target without heat diffusion to the sur-
rounding tissue. On the basis of these principles, 
laser parameters can be tailored to destruction of 
the tissue confined to microscopic sites of selec-
tive light absorption in the skin, such as blood cells 
and pigmented cells, with minimal collateral ther-
mal damage (10).
LASER THERAPY OF SOLAR 
LENTIGINES
 Laser therapy is superior to the traditional meth-
ods in treating solar lentigines, with a minimal risk 
of permanent sequels. In solar lentigines, melanin 
is the chromophore which is the target for selec-
tive destruction. Early laser technologies were lim-
ited to the use of continuous wave (CW) lasers 
for pigment removal (ruby, argon, CO2 systems), 
which yielded high rates of hypertrophic scarring 
and pigmentary alteration because the nonse-
lective tissue injury involved adjacent cutaneous 
structures (11,12). 
 To obtain selective photothermolysis of mela-
nin, solar lentigines must be treated with laser light 
of a wavelength appropriate to absorption charac-
teristics of melanin. Because melanin has a broad 
absorption spectrum, a variety of different laser 
systems which emit wavelengths of 500-1100 nm 
may be used to remove melanin from the skin. 
However, treatment efficacy decreases as the 
wavelength increases. Ideally, the pulse duration 
should be shorter than the thermal relaxation time 
of melanin, which is relatively short, ranging from 
50 to 500 ns (13).  
 The development of short-pulsed, Q-switched 
(QS) lasers (pulse duration 5-100 ns) enabled 
eradication of pigmented lesions with a minimal 
risk of untoward effects. These lasers have elec-
tro-optical shutters that permit release of stored 
energy within the laser cavity in short high-en-
ergy bursts, delivering power outputs as high as 
109 W. The following pigment-selective, short 
pulse lasers are in clinical use for solar lentigo 
removal today: pigmented lesion pulsed dye la-
ser (510 nm), Q-switched ruby laser (694 nm), 
Q-switched alexandrite laser (755 nm) and Q-
switched Nd:YAG laser (1064 nm), which can be 
frequency-doubled to produce visible green light 
at a wavelength of 532 nm. Usually, a series (two 
or more) of laser sessions at six- to eight-week 
intervals are necessary to achieve complete re-
moval of the lesion (11,12).
Pigmented lesion dye laser
 The pigmented lesion dye laser emits light at a 
510 nm wavelength and pulse duration of 300 ns, 
which enables targeting superficial melanosomes. 
Although no longer commercially available, this 
laser is effective in the treatment of lentigines and 
other epidermal pigmented lesions. Immediately 
after irradiation, an ash-grey discoloration of the 
skin develops, and up to 50% of patients develop 
purpura due to absorption of laser energy by oxy-
hemoglobin. A fine crust typically forms over the 
laser treated area and peels off after in a week 
(11,12,14).
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Q-switched ruby laser (QSRL)
 The Q-switched ruby laser (QSRL) emits vis-
ible red light at a wavelength of 694 nm, pulse du-
ration of 28 to 50 ns, spot size of 3.5 to 6.5 mm, 
and repetition rate of 1 Hz. This wavelength is 
so well-absorbed by melanin that permanent hy-
popigmentation and depigmentation may occur in 
darker-skinned individuals. The absorption of ruby 
laser energy by hemoglobin is minimal. Similar 
to the aforementioned laser, a crust is formed at 
the site of laser irradiation and peels off in several 
days (15-17).
Q-switched alexandrite laser
 This laser operates at a wavelength of 755 nm, 
with pulse duration of 50-100 ns, spot size of 2-4 
mm, and repetition rate of 1-15 Hz. Due to its lon-
ger pulse duration, the alexandrite laser produces 
less tissue splatter during laser irradiation. In ad-
dition, its longer wavelength permits deeper tissue 
penetration and less unwanted hypopigmentation 
compared with QSRL. Postoperative healing is 
similar to that with other QS pigment-specific la-
sers, yet the lesion produced is considered less 
severe (11,12,18).
Q-switched Nd:YAG laser
 It emits 1064-nm light but can also be frequen-
cy-doubled using a potassium diphosphate crystal 
to produce visible green light at a wavelength of 
532 nm. These systems usually have pulse dura-
tion ranging from 10 to 20 ns, spot size of 1.5-4 
mm, and repetition rate of 1-10 Hz. Melanin has a 
strong affinity for 532-nm green light, whereas the 
longer 1064-nm wavelength penetrates the skin 
more deeply but with a lower melanin absorption 
coefficient. After the use of smaller spot sizes, tis-
sue splatter usually occurs, leading to crusting that 
may take several weeks to fully resolve (19,20).
 A recent study compared the efficacy of three 
lasers and liquid nitrogen in the treatment of solar 
lentigines. Laser therapy was found to be superior 
to liquid nitrogen in this indication. Furthermore, 
the frequency doubled QS Nd:YAG laser was 
more effective compared to HGM K1 krypton laser 
and 532 nm diode-pumped vanadate laser (21).
CASE REPORT
 A 58-year-old woman with type II skin presented 
to our Department with uniformly a colored brown 
macule with sharply demarcated polycyclic bor-
ders, which persisted on her right cheek for about 
30 years with slow progression. The size of the le-
sion was 20x17 mm (Fig. 1). There was no family 
history of skin diseases. The lesion was clinically 
evaluated as solar lentigo. However, according 
to the ABCD rule (Asymmetry, irregular Borders, 
Color variegation, Diameter larger than 6 mm), 
the differential diagnosis included lentigo maligna. 
Therefore, biopsy was performed and histological 
analysis revealed thickened epidermis, papillo-
matosis and hyperpigmentation of the basal layer 
of the epidermis, which was consistent with solar 
lentigo. The lesion was treated with QSRL at a 
fluence of 2,5 J/cm2 using nonoverlapping 5-mm 
spot size. After the first session, the lesion was 
partially lightened (Fig. 2), and the treatment was 
repeated with the same parameters 6 weeks later. 
Figure 1. Solar lentigo lesion before the treatment 
with QSLR.
Figure 2. The result of one session with QSRL.  
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After the second treatment we observed total re-
moval of the pigment without unwanted sequels 
(Fig. 3).
CONCLUSION
 Understanding the effects of laser light on the 
skin and using this knowledge to manufacture 
new usable technology have provided selective 
removal of different skin lesions, including solar 
lentigines. Nowadays, laser therapy is considered 
to be the treatment of choice for solar lentigines 
(22). However, responses to treatment with lasers 
are variable. Treatment failure may occur if pig-
ment remains at a greater tissue depth than the 
laser can reach, or in case of repigmentation by 
stimulated melanocytes within adnexal epithelium. 
Thus, the patient should be informed on the risk 
of pigmentary recurrence and the need of repeat 
treatment. As the risk of repigmentation is en-
hanced with UV light exposure, photoprotection is 
strongly recommended (11). 
 The essential question in removing pigmented 
lesions with lasers is whether the lesion has atypi-
cal features or a malignant potential. There are no 
definitive answers, and decision should always be 
made on individual basis. Some authors recom-
mend dermoscopy in every case of solar lentigo, 
regardless of the benign clinical appearance, as 
in their opinion solar lentigo lesions are almost al-
ways “ABCD-positive” (23). Furthermore, if there 
is any doubt whether the lesion is benign, then 
biopsy for histological evaluation is mandatory 
(11,24).
 When patients are properly selected and stan-
dard treatment parameters are followed, the high-
energy, short-pulsed lasers are safe and effective 
tools for removal of solar lentigines.
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Nivea cream for your skin in the springtime, year 1934.
(from the collection of Mr. Zlatko Puntijar)
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